Search

Displaying results 1261 - 1270 of 8468 in total
  1. Drug

    Nandrolone decanoate

    go.drugbank.com/drugs/DB08804
    ApprovedIllicitInvestigational

    [A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic … Nandrolone decanoate, also known as nandrolone caprinate, is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile

  2. Drug

    Ginseng

    go.drugbank.com/drugs/DB01404
    ApprovedInvestigationalNutraceutical

    Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties

    Mixtures: Aps
  3. Drug

    Tegafur-uracil

    go.drugbank.com/drugs/DB09327
    Approved

    It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.

  4. Drug

    Cryptenamine

    go.drugbank.com/drugs/DB00785
    Approved

    It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. … Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.

  5. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    : it has been used as part of multi-agent chemotherapy. … [L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic

  6. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

  7. Drug

    Poloxamer 188

    go.drugbank.com/drugs/DB11333
    Approved

    The use of P188 as a potential treatment in different pathological conditions, such as chronic microvascular diseases and skeletal muscle deficiencies, is under investigation [A27217]. … P188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217].

  8. Drug

    Ceritinib

    go.drugbank.com/drugs/DB09063
    ApprovedInvestigational

    This occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance. … The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.

  9. Drug

    Aspartic acid

    go.drugbank.com/drugs/DB00128
    ApprovedInvestigationalNutraceutical

    One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

    Mixtures: LEVAMIN PAD
  10. Drug

    Decamethonium

    go.drugbank.com/drugs/DB01245
    Approved

    It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.